A study on N-glycosylation and its role in AL amyloidosis
Part of Blood & lymphatic, Cancer, Heart & circulation, Hormones & metabolism, Immune system & allergy clinical trials.
This research study looks at how certain sugar molecules (N-glycosylation) on proteins may play a role in a disease called AL amyloidosis. Researchers will study blood samples from people with related plasma cell disorders to learn more about these sugars, which could help with diagnosis and treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a plasma cell disorder such as AL amyloidosis, MGUS, or multiple myeloma.
- You are over 18 years old.
- You are willing to have a blood sample (and possibly a bone marrow sample) taken for research.
- You are willing to let researchers use your medical information and leftover samples for this study.
- You have not already achieved a complete response to treatment for your condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a specific gene (IGLV1-44) affects two rare diseases: AL amyloidosis and POEMS syndrome. It involves a blood draw and possibly a bone marrow sample to learn more about how the gene works in these conditions.
This study collects information from adults with systemic AL amyloidosis to better understand the disease and outcomes. Because it includes pre-treatment records and follows people over time, it may help future patients by improving knowledge of how AL amyloidosis progresses and responds to care.
This study is for people who are newly diagnosed with either a very early blood condition (MGUS or smoldering myeloma) or AL amyloidosis, and who have not yet had treatment. It aims to help doctors better diagnose and manage these conditions in Italy.
This trial uses special imaging scans to detect amyloidosis (abnormal protein buildup) early in people who have monoclonal gammopathy (an abnormal blood protein). The goal is to find amyloidosis before it causes serious organ damage.
This study collects blood and other samples, along with health information, from people who have—or might have—amyloidosis. It aims to improve understanding of the disease and support future treatments.
This study collects health information and, if needed, samples from people diagnosed with certain blood disorders related to plasma cells. Sharing your information may help researchers better understand these diseases and improve future care.
Hear when a new AL Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.